Clinical trials: Atopic Skin
Atopic Dermatitis
Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit
The purpose of this research study is to better understand how the study drug works when people use it to treat atopic dermatitis.
- Trial name
- NCT00654355
- Testing
- tacrolimus ointment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University
Atopic Dermatitis
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
This is a randomized open label study to evaluate the long term safety of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT03654755
- Testing
- ASN002
- Where
- 38 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Asana BioSciences
Atopic Dermatitis
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with…
- Trial name
- ATLAS (NCT05155085)
- Testing
- AK002
- Where
- 55 sites in United States, Germany
- Volunteers
- 131 people
- Sponsor
- Allakos Inc.
Atopic Dermatitis
Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis
The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis
- Trial name
- D2213C00001 (NCT02347176)
- Testing
- Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3
- Where
- 57 sites in United States, Australia and 4 more
- Volunteers
- 204 people
- Sponsor
- MedImmune LLC
Atopic Dermatitis, Plaque Psoriasis
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you…
- Trial name
- NCT05375955
- Testing
- PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Atopic Dermatitis
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
- Trial name
- NCT03002571
- Testing
- IDP-124 Lotion, IDP-124 Vehicle Lotion
- Where
- United States
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD7 (NCT03733301)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 68 sites in Argentina, Australia and 8 more
- Volunteers
- 329 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
Atopic dermatitis (AD) is a common inflammatory skin disorder that adversely affects most aspects of everyday life in majority of patients. It has a prevalence of up to 3-4% of adults and up to 25% among children.
- Trial name
- NCT01941537
- Testing
- ILV-094
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Rockefeller University
Atopic Dermatitis
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD).
- Trial name
- NCT01949311
- Testing
- Dupilumab
- Where
- 432 sites in United States, Australia and 26 more
- Volunteers
- 2,733 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
This study determines the Maximum Tolerable Dose (MTD) by maximum BSA percentage treated and evaluates safety and efficacy of 1.1% w/w AMTX-100 CF versus placebo (vehicle).
- Trial name
- NCT04313400
- Testing
- 1.1% w/w AMTX-100 CF-part1, 1.1% w/w AMTX-100 CF3-part2
- Where
- 11 sites in United States
- Volunteers
- 91 people
- Sponsor
- Amytrx Therapeutics, Inc.
Atopic Dermatitis
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
The purpose of this study is to determine the effect of GBR 830 on biomarkers in atopic dermatitis to enable further studies in this indication.
- Trial name
- NCT02683928
- Testing
- GBR 830
- Where
- 17 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Ichnos Sciences SA
Atopic Dermatitis
A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India.
- Trial name
- NCT05375929
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 15 sites in India
- Volunteers
- 200 people
- Sponsor
- Pfizer
Atopic Dermatitis
Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
This study is being conducted to provide data on efficacy, safety, tolerability and PK of multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of mild to moderate atopic dermatitis (AD).
- Trial name
- NCT03903822
- Testing
- PF-06700841
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 292 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
The co-primary objectives of the study are to: Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD).
- Trial name
- ROCKET-Horizon (NCT05651711)
- Testing
- Rocatinlimab
- Where
- 197 sites in United States, Australia and 19 more
- Volunteers
- 726 people
- Sponsor
- Amgen
Atopic Dermatitis (AD)
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
The purpose of this study is to understand the effect that T helper 2 (Th2) blockade has on well-described pathophysiological features of Atopic Dermatitis (AD), for example: barrier, epidermal activation, dysbiosis and epidermal…
- Trial name
- NCT03389893
- Testing
- Dupilumab
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis
A randomized, double-blind, placebo-controlled single and multiple dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 gel after transdermal administration in…
- Trial name
- Shaperon (NCT03492398)
- Testing
- HY209
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Shaperon
Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451013 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-2 (NCT03575871)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 391 people
- Sponsor
- Pfizer
Atopic Dermatitis
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects…
- Trial name
- NCT02780167
- Testing
- PF-04965842
- Where
- 64 sites in United States, Australia and 3 more
- Volunteers
- 269 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
- Trial name
- ADmirable (NCT05372419)
- Testing
- Lebrikizumab
- Where
- 36 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
This was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18…
- Trial name
- NCT05018806
- Testing
- Rilzabrutinib
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- Sanofi